Agios Pharmaceuticals, Inc. (AGIO) vs Trevi Therapeutics, Inc. (TRVI)
A side-by-side comparison of Agios Pharmaceuticals, Inc. and Trevi Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AGIO
Agios Pharmaceuticals, Inc.
$31.72HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TRVI
Trevi Therapeutics, Inc.
$13.18HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AGIO vs TRVI
growth of $100 · dividends reinvested · last 7yAGIO -38.1% (-6.6%/yr)TRVI +73.9% (+8.2%/yr)TRVI compounded faster over this window
AGIO TRVI
AGIO vs TRVI: by the numbers
- •AGIO is the larger company ($1.89B vs $1.87B market cap).
- •Both run net losses; TRVI's is the smaller (0.00% vs -418.24% net margin).
Metrics side by side
Valuation
| Metric | AGIO | TRVI |
|---|---|---|
| P/S ratio | 19.26 | N/A |
| P/B ratio | 1.85 | 5.82 |
Profitability
| Metric | AGIO | TRVI |
|---|---|---|
| Gross margin | 78.67% | 0.00% |
| Operating margin | -873.87% | 0.00% |
| Net margin | -418.24% | 0.00% |
| ROE | -40.09% | -15.90% |
| ROIC | -44.21% | -18.51% |
Growth (annualized)
| Metric | AGIO | TRVI |
|---|---|---|
| Revenue CAGR (5Y) | 4.54% | N/A |
| Total return CAGR (5Y) | -6.59% | 61.74% |
Frequently asked
- How have AGIO and TRVI total returns compared?
- Over the past 5 years, AGIO delivered -6.59% and TRVI delivered 61.74% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.